|
Charles Heidelberger (December 23, 1920 – January 18, 1983) was a cancer researcher who developed and patented an anticancer drug called 5-Fluorouracil〔(National Cancer Institute: 150 Years of Advances Against Cancer - 1940s-1950s )〕 that remains widely used against cancers of the stomach, colon and breast.〔(New York Times Obituary: Charles Heidelberger, A Cancer Researcher )〕 He was also director of basic research at the University of Southern California's Comprehensive Cancer Center.〔(The National Academies Press, Biographical Memoirs, Charles Heidelberger )〕 He received American Cancer Society National Award in 1974.〔(Newsarchive )〕 Heidelberger served on editorial boards of various scientific journals: Cancer Research, Molecular Pharmacology, Biochemical Pharmacology, the International Journal of Cancer, in Vitro, and the Journal of Medicinal Chemistry.〔(Cancer Research Journal, Charles Heidelberger 1920-1983 )〕 He served as Director for Basic Research of the USC Cancer Center, and was a Distinguished Professor at the University of Southern California. == Notable Awards and Distinctions == Heidelberger received the following awards: * Elected to the National Academy of Science, U.S.A. in 1978. * The Langer-Teplitz Award for Cancer Research in 1958. * Walter I. Hubert Lecturer for the British Association for Cancer Research in 1969. * Lucy Wortham James Award of the James Ewing Society (1969) * G.H.A. Clowes Memorial Award and Lectureship of the American Association for Cancer Research (1970) * American Cancer Society National Award (1974) * Lila Gruber Award of the American Academy of Dermatology (1976) * Papanicolaou Award for Scientific Achievement (1978) * Chemical Industry Institute of Toxicology Founder’s Award (1982) * C. Chester Stock Award of the Memorial Sloan-Kettering Cancer Center (1982) * The first Athayde International Cancer Prize 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Charles Heidelberger」の詳細全文を読む スポンサード リンク
|